SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals zooms on getting nod to launch favipiravir for treatment of COVID-19 patients

22 Jun 2020 Evaluate
Glenmark Pharmaceuticals is currently trading at Rs. 541.75, up by 132.65 points or 32.42% from its previous closing of Rs. 409.10 on the BSE.

The scrip opened at Rs. 450.00 and has touched a high and low of Rs. 572.70 and Rs. 450.00 respectively. So far 3354299 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 572.70 on 22-Jun-2019 and a 52 week low of Rs. 168.00 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 572.70 and Rs. 387.25 respectively. The current market cap of the company is Rs. 15321.73 crore.

The promoters holding in the company stood at 46.62%, while Institutions and Non-Institutions held 35.26% and 18.12% respectively.

Glenmark Pharmaceuticals has received the manufacturing and marketing approval from India's drug regulator to launch the oral antiviral drug Favipiravir (FabiFlu) for the treatment of mild to moderate COVID-19 patients in India.

This approval has been granted based on evaluation of data and in consultation with the Subject Expert Committee, as part of accelerated approval process, considering the emergency situation and unmet medical need of the COVID-19 outbreak. It is for restricted emergency use in India. Restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation.

Glenmark Pharmaceuticals (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

2242.80 -5.10 (-0.23%)
20-Apr-2026 11:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1674.00
Dr. Reddys Lab 1236.85
Cipla 1237.20
Zydus Lifesciences 941.70
Lupin 2324.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×